Gap down on NYSE on slightly increased volume and a small rise after market close. I think this is capitulation. These "new" weight loss drugs are expensive, have GI side effects and have to be injected daily. The demographic most affected by obesity won't have the stamina to continue injecting themselves nor afford the $$$ on top of all the other medications they take for blood pressure, cholesterol etc etc, plus repeat Dr visits. These drugs will end up being a complimentary treatment for OSA for those that can afford them with CPAP devices. The short sellers have had their fun IMO.
Ann: ResMed Announces Results for the Fourth Quarter of FY2023, page-284
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.84B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.729M | 260.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |